The experimental SchistoShield vaccine triggered strong B-cell and T-cell immune memory in early U.S. and African clinical trials.

Shilpa Biologicals says India has the scientific talent and infrastructure to be a trusted partner in ADC drug substance manufacturing.

A new study published in Cell Death Discovery titled, “Sustained dysregulation of iron and glutathione homeostasis induces chronoferroptosis, a persistent ferroptotic adaptation in neuronal ...

Merck & Co. will partner with Protillion Biosciences to discover multiple new therapy candidates, through a collaboration ...

The discussion covered plans to increase the agency's headcount and to expedite early through late-stage clinical development in the U.S.

Researchers say approach could be useful for both initial treatment of bladder cancer as well as treatment refractory subsets of tumors.

The pipeline includes clinical and IND stage mono and multispecific antibodies that target immune-mediated inflammatory diseases.

Researchers developed the first human antibody cocktail to completely protect against the lethal Nipah and Hendra virus infection in preclinical models.

Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life ...

AI‑guided analysis surfaces a new CAR T target with multi‑cancer activity, as Penn researchers validate GPNMB‑directed CAR T cells in preclinical models.

Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...

For NK cell expansion, engineered ARH-77 cells may end the current bottleneck by increasing yield by more than 100,000-fold in one month.